Targeted therapy before surgery for a type of jaw tumor
Treatments studied
Part of Cancer clinical trials.
This trial tests whether taking two targeted drugs (dabrafenib and trametinib) before surgery can shrink a specific type of jaw tumor called ameloblastoma. The tumor must have a certain genetic change (BRAF V600E mutation) and require a large jaw surgery. The goal is to see if the drugs make surgery less extensive or more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have a type of jaw tumor called solid/multicystic ameloblastoma with the BRAF V600E gene change (tested by a special lab method)
- Your tumor is large enough that your doctors recommend removing a piece of the jawbone (segmental resection)
- The cancer has not spread to other parts of your body
- You are generally in good health (able to do daily activities) and your organs work well (kidney, liver, blood counts)
- You have not taken targeted drugs for BRAF or MEK before and are willing to use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking targeted drugs before surgery can reduce the amount of jawbone that needs to be removed, compared to going straight to surgery. It is for people with a specific type of jaw tumor that has a BRAF V600E mutation.
This trial tests cetuximab combined with dabrafenib and tislelizumab in people with advanced colorectal cancer that has a BRAF V600E mutation. It’s for cases where the first standard treatment didn’t work or couldn’t be tolerated, aiming to shrink tumors and improve control of the disease.
This trial tests a targeted treatment given before and after surgery for people with a specific type of early-stage lung cancer that has a BRAF V600 or MET exon 14 mutation. The goal is to see if the treatment helps shrink the tumor before surgery and prevent it from coming back afterward.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This Phase 2 trial tests a targeted treatment for adults with papillary craniopharyngioma that has a specific BRAF change (V600E). It may help shrink or control the tumor, especially when surgery is not expected to remove it safely.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
Hear when a new Ameloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.